World Journal of Surgery

, Volume 28, Issue 10, pp 995–1000 | Cite as

Immunohistochemical Study of DPC4 and p53 Proteins in Gallbladder and Bile Duct Cancers

  • Shih-Chang Chuang
  • King-Teh Lee
  • Kun-Bow Tsai
  • Pai-Ching Sheen
  • Eishi Nagai
  • Kazuhiro Mizumoto
  • Masao Tanaka
Original Scientific Reports


Gallbladder and bile duct carcinomas belong to the family of biliary tract tumors, but they demonstrate different clinical behavior. We evaluated a series of biliary tract carcinomas to determine whether they also had genotypic differences by analysis of the tumor suppressor genes DPC4 and p53. Twenty-one gallbladder cancers, 20 intrahepatic bile duct carcinomas, and 10 extrahepatic bile duct carcinomas were retrieved from the surgical pathology files of Kaohsiung Medical University Hospital. Sections were immunostained with monoclonal antibodies to the DPC4 and P53 proteins. Statistical differences between gallbladder cancer and bile duct carcinomas were determined using ?2 analysis or the Fisher’s exact test, when appropriate. Two of the 21 gallbladder cancers (9.5%), 7 of the 20 intrahepatic bile duct carcinomas (35%), and five of the 10 extrahepatic bile duct carcinomas (50%) were negatively labeled for DPC4. The differences were significant between gallbladder carcinoma and both intrahepatic bile duct carcinomas (p = 0.023) and extrahepatic bile duct carcinomas (p = 0.012). A higher frequency of P53 overexpression was found in gallbladder cancers (61.9%) than in intrahepatic bile duct carcinomas (26.3%) (p = 0.024). This study suggests that the DPC4 gene may play a limited role in gallbladder carcinoma; however, p53 gene mutation is more frequently found in gallbladder cancers. In contrast, DPC4 deletion may be more common in bile duct carcinomas, especially in those arising from the extrahepatic bile duct. These findings support the concept that gallbladder and bile duct carcinomas are different tumors with differing etiologies and tumorigenesis.


Gallbladder Cancer Choledochal Cyst Gallbladder Carcinoma Bile Duct Carcinoma Positive Label 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Adanja, B, Gledovic, Z, Pekmezovic, T,  et al. 2000Mortality trends of malignant tumours of digestive organs in Belgrade, Yugoslavia, 1975-1997Dig. Liver Dis.32386391CrossRefPubMedGoogle Scholar
  2. 2.
    Lazcano-Ponce, EC, Miquel, JF, Munoz, N,  et al. 2001Epidemiology and molecular pathology of gallbladder cancerCA Cancer J. Clin.51349364PubMedGoogle Scholar
  3. 3.
    Urbani, C, Palmer, K 2001Drug-based helminth control in Western Pacific countries: a general perspectiveTrop. Med. Int. Health6935944CrossRefPubMedGoogle Scholar
  4. 4.
    Groen, PC, Gores, GJ, LaRusso, NF,  et al. 1999Biliary tract cancersN. Engl. J. Med.34113681378Google Scholar
  5. 5.
    Baxter, I, Garden, OJ 1999Surgical palliation of carcinoma of the gallbladderHepatogastroenterology4615721577PubMedGoogle Scholar
  6. 6.
    Sergi, C, Adam, S, Kahl, P,  et al. 2000The remodeling of the primitive human biliary systemEarly Hum. Dev.58167178CrossRefPubMedGoogle Scholar
  7. 7.
    Eyken, P, Sciot, R, Callea, F,  et al. 1988The development of the intrahepatic bile ducts in man: a keratin-immunohistochemical studyHepatology815861595PubMedGoogle Scholar
  8. 8.
    Vijayan, V, Tan, CE 1997Developing human biliary system in three dimensionsAnat. Rec.249389398CrossRefPubMedGoogle Scholar
  9. 9.
    Hahn, SA, Schutte, M, Hoque, AT,  et al. 1996DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1Science271350353PubMedGoogle Scholar
  10. 10.
    Zhang, Y, Feng, X, We, R,  et al. 1996Receptor-associated Mad homologues synergize as effectors of the TGF-beta responseNature383168172CrossRefPubMedGoogle Scholar
  11. 11.
    Montgomery, E, Goggins, M, Zhou, S,  et al. 2001Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defectsAm. J. Pathol.158537542PubMedGoogle Scholar
  12. 12.
    Lagna, G, Hata, A, Hemmati-Brivanlou, A,  et al. 1996Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathwaysNature383832836CrossRefPubMedGoogle Scholar
  13. 13.
    Dai, JL, Turnacioglu, KK, Schutte, M,  et al. 1998Dpc4 transcriptional activation and dysfunction in cancer cellsCancer Res.5845924597PubMedGoogle Scholar
  14. 14.
    Argani, P, Shaukat, A, Kaushal, M,  et al. 2001Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ductsCancer9113321341Google Scholar
  15. 15.
    Shiraishi, K, Kusano, N, Okita, S,  et al. 1999Genetic aberrations detected by comparative genomic hybridization in biliary tract cancersOncology574249CrossRefPubMedGoogle Scholar
  16. 16.
    Hahn, SA, Bartsch, D, Schroers, A,  et al. 1998Mutations of the DPC4/Smad4 gene in biliary tract carcinomaCancer Res.5811241126PubMedGoogle Scholar
  17. 17.
    Barrett, MT, Schutte, M, Kern, SE,  et al. 1996Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinomaCancer Res.5643514353PubMedGoogle Scholar
  18. 18.
    Nagatake, M, Takagi, Y, Osada, H,  et al. 1996Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancersCancer Res.5627182720PubMedGoogle Scholar
  19. 19.
    Calonge, MJ, Massague, J 1999Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cellsJ. Biol. Chem.2743363733643CrossRefPubMedGoogle Scholar
  20. 20.
    Schwarte-Waldhoff, I, Klein, S, Blass-Kampmann, S,  et al. 1999DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expressionOncogene1831523158CrossRefPubMedGoogle Scholar
  21. 21.
    Winter, JP, Roelen, BA, Dijke, P,  et al. 1997DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cellsOncogene1418911899CrossRefPubMedGoogle Scholar
  22. 22.
    Wang, D, Kanuma, T, Mizunuma, H,  et al. 2000Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancerCancer Res.6045074512PubMedGoogle Scholar
  23. 23.
    Zhou, Y, Kato, H, Shan, D,  et al. 1999Involvement of mutations in the DPC4 promoter in endometrial carcinoma developmentMol. Carcinog.256472CrossRefPubMedGoogle Scholar
  24. 24.
    Chang, HJ, Kim, SW, Kim, YT,  et al. 1999Loss of heterozygosity in dysplasia and carcinoma of the gallbladderMod. Pathol.12763769PubMedGoogle Scholar
  25. 25.
    Gannon, JV, Greaves, R, Iggo, R,  et al. 1990Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant formEMBO J.915951602PubMedGoogle Scholar
  26. 26.
    Washington, K, Gottfried, MR 1996Expression of p53 in adenocarcinoma of the gallbladder and bile ductsLiver1699104PubMedGoogle Scholar
  27. 27.
    Fujii, K, Yokozaki, H, Yasui, W,  et al. 1996High frequency of p53 gene mutation in adenocarcinomas of the gallbladderCancer Epidemiol. Biomarkers Prev.5461466PubMedGoogle Scholar
  28. 28.
    Nakeeb, A, Lipsett, PA, Lillemoe, KD,  et al. 1996Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinomaAm. J. Surg.171147152CrossRefPubMedGoogle Scholar
  29. 29.
    Flavell, DJ 1981Liver-fluke infection as an aetiological factor in bile-duct carcinoma of manTrans. R. Soc. Trop. Med. Hyg.75814824CrossRefPubMedGoogle Scholar
  30. 30.
    Kubo, S, Kinoshita, H, Hirohashi, K,  et al. 1995Hepatolithiasis associated with cholangiocarcinomaWorld J. Surg.19637641PubMedGoogle Scholar
  31. 31.
    Kim, YT, Byun, JS, Kim, J,  et al. 2003Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasisHepatogastroenterology50812PubMedGoogle Scholar
  32. 32.
    Boberg, KM, Bergquist, A, Mitchell, S,  et al. 2002Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentationScand. J. Gastroenterol.3712051211CrossRefPubMedGoogle Scholar
  33. 33.
    Chalasani, N, Baluyut, A, Ismail, A,  et al. 2000Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control studyHepatology31711CrossRefPubMedGoogle Scholar
  34. 34.
    Parkin, DM, Ohshima, H, Srivatanakul, P,  et al. 1993Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and preventionCancer Epidemiol. Biomarkers Prev.2537544PubMedGoogle Scholar
  35. 35.
    Lesurtel, M, Regimbeau, JM, Farges, O,  et al. 2002Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countriesEur. J. Gastroenterol. Hepatol.1410251027Google Scholar
  36. 36.
    Patel, T 2001Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United StatesHepatology3313531357CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2004

Authors and Affiliations

  • Shih-Chang Chuang
    • 1
  • King-Teh Lee
    • 1
  • Kun-Bow Tsai
    • 2
  • Pai-Ching Sheen
    • 1
  • Eishi Nagai
    • 3
  • Kazuhiro Mizumoto
    • 3
  • Masao Tanaka
    • 3
  1. 1.Division of Hepatobiliary Surgery, Department of SurgeryKaohsiung Medical University HospitalKaohsiungTaiwan
  2. 2.Department of PathologyKaohsiung Medical University HospitalKaohsiungTaiwan
  3. 3.Department of Surgery and Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations